Company: RCUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001724521-25-000101
Chunk: 196

Company: Arcus Biosciences, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 196
---
)$(97)Other comprehensive loss— — — (1)Comprehensive income (loss)$— $(93)$(112)$(98)

See accompanying notes.

2

Table of Contents

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions, except per share amounts)

(unaudited)

June 30,2025December 31,2024ASSETS Current assets:Cash and cash equivalents$248 $150 Marketable securities663 828 Receivable from collaboration partners ($4 and $6 from a related party)15 20 Prepaid expenses and other current assets20 18 Total current assets946 1,016  Long-term marketable securities16 14 Property and equipment, net44 47 Other noncurrent assets 69 73 Total assets$1,075 $1,150  LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable ($13 and $— to a related party)$29 $18 Deferred revenue ($71 and $85 to a related party)71 85 Other current liabilities110 123 Total current liabilities210 226  Deferred revenue, noncurrent ($60 and $234 to a related party)60 234 Long-term debt97 48 Other noncurrent liabilities159 157  Commitments Stockholders’ equity:Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 106.4 shares in 2025 and 92.2 shares in 2024 issued and outstanding1,793 1,617 Accumulated deficit(1,244)(1,132)Total stockholders’ equity549 485 Total liabilities and stockholders’ equity$1,075 $1,150 

See accompanying notes.

3

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(In millions)

(unaudited)

Number of shares of common stockCommon stock and additional paid-in capitalAccumulated deficit Accumulatedothercomprehensive loss Totalstockholders’ equity Balance at December 31, 202375.5$1,311 $(849)$— $462 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' equity